Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Plasma and cellular ivacaftor concentrations in patients with cystic fibrosis.

Pediatric pulmonology - 1 Nov 2022

Guimbellot Jennifer S, Ryan Kevin J, Anderson Justin D, Parker Kennedy L, Victoria Odom Lauren, Rowe Steven M, Acosta Edward P

Abstract excerpt

Access to cystic fibrosis transmembrane conductance regulator (CFTR) modulators has been gradually increasing for people with cystic fibrosis, the first of which was ivacaftor, a CFTR potentiator that is part of all clinically available modulator treatments. In this study, we hypothesized that the steady-state concentrations in blood and tissue are highly variable in patients taking ivacaftor in a real-world...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aminophenols
Share to Benzodioxoles

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cystic Fibrosis

Share to Cystic Fibrosis Transmembrane Conductance Regulator

Share to Mutation

Share to Quinolones

Source

Open in PubMed Open full text

Identifiers

PMID: 35927224
DOI: 10.1002/ppul.26093
PMCID: PMC9588676

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Plasma and cellular ivacaftor concentrations in patients with cystic fibrosis.PMID 35927224Read ↗

The U.S. Food and Drug Administration's Experience with Ivacaftor in Cystic Fibrosis. Establishing Efficacy Using In Vitro Data in Lieu of a Clinical Trial.Semantic proximity Read ↗

Real-life experience with a generic formulation of lumacaftor-ivacaftor in patients with cystic fibrosis homozygous for the Phe508del CFTR mutation.Semantic proximity Read ↗

Ivacaftor in subjects with cystic fibrosis who are homozygous for the F508del-CFTR mutation.Semantic proximity Read ↗

Real-world data confirm elexacftor/tezacaftor/ivacaftor modulators halves sweat chloride concentration in eligible people with cystic fibrosis.Semantic proximity Read ↗

Clinical mechanism of the cystic fibrosis transmembrane conductance regulator potentiator ivacaftor in G551D-mediated cystic fibrosis.Semantic proximity Read ↗

Multimatrix Monitoring of CFTR Modulators Reflecting Systemic Exposure, Airway Targeting, and Sweat Compartment in People with Cystic FibrosisSemantic proximity Read ↗

Predicting Cavg of CFTR Modulators Using Sparse Sampling: Evaluating Single and Multiple Time Points with Machine Learning ApproachesSemantic proximity Read ↗

Long term clinical effectiveness of ivacaftor in people with the G551D CFTR mutation.Semantic proximity Read ↗

Predicting Cavg of CFTR Modulators Using Sparse Sampling: Evaluating Single and Multiple Time Points with Machine Learning ApproachesSemantic proximity Read ↗

Predicting Cavg of CFTR Modulators Using Sparse Sampling: Evaluating Single and Multiple Time Points with Machine Learning ApproachesSemantic proximity Read ↗

Safety, pharmacokinetics, and pharmacodynamics of ivacaftor in patients aged 2-5 years with cystic fibrosis and a CFTR gating mutation (KIWI): an open-label, single-arm study.Semantic proximity Read ↗

Ivacaftor treatment of cystic fibrosis in children aged 12 to <24 months and with a CFTR gating mutation (ARRIVAL): a phase 3 single-arm study.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.